These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11230468)

  • 1. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.
    Curtin JP; Blessing JA; Webster KD; Rose PG; Mayer AR; Fowler WC; Malfetano JH; Alvarez RD
    J Clin Oncol; 2001 Mar; 19(5):1275-8. PubMed ID: 11230468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Moore D; Lentz SS; Photopulos G
    J Clin Oncol; 1996 Mar; 14(3):792-5. PubMed ID: 8622025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Gershenson DM; McGehee R
    J Clin Oncol; 1999 Sep; 17(9):2676-80. PubMed ID: 10561341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Buller RE; Mannel RS; Webster KD
    Gynecol Oncol; 2003 May; 89(2):267-70. PubMed ID: 12713990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
    Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Muggia FM; Blessing JA; Waggoner S; Berek JS; Monk BJ; Sorosky J; Pearl ML
    Gynecol Oncol; 2005 Jan; 96(1):108-11. PubMed ID: 15589588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
    Vaughn DJ; Broome CM; Hussain M; Gutheil JC; Markowitz AB
    J Clin Oncol; 2002 Feb; 20(4):937-40. PubMed ID: 11844814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Markman M; Brady MF; Spirtos NM; Hanjani P; Rubin SC
    J Clin Oncol; 1998 Aug; 16(8):2620-4. PubMed ID: 9704711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
    Lhommé C; Fumoleau P; Fargeot P; Krakowski Y; Dieras V; Chauvergne J; Vennin P; Rebattu P; Roche H; Misset JL; Lentz MA; Van Glabbeke M; Matthieu-Boué A; Mignard D; Chevallier B
    J Clin Oncol; 1999 Oct; 17(10):3136-42. PubMed ID: 10506610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
    Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
    Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.